David Carlile

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings, Franck Morschhauser, Gloria Iacoboni et al. · Journal of Clinical Oncology · 2021 · 413 citations · Full text

Life Sciences, Immunology, Oncology +17

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i>-Mutant Advanced Non–Small Cell Lung Cancer

Pasi A. Jänne, Michel M. van den Heuvel, Fabrice Barlési et al. · JAMA · 2017 · 332 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

Gilles Salles, Franck Morschhauser, Thierry Lamy et al. · Blood · 2012 · 190 citations · Full text

Pharmacy, Hematology, Oncology +17

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

Laurie H. Sehn, Sarit Assouline, Douglas A. Stewart et al. · Blood · 2012 · 147 citations

Life Sciences, Hematology, Immunology +13

Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam.

David Carlile, Katayoun Zomorodi, J. Brian Houston · PubMed · 1997 · 121 citations

Pharmacy, Biochemistry, Pharmacology +17